N5334 Final Questions and Answers
A+ Graded (2025)
Prescribing .basics .- .CORRECT .ANSWER-Prescribing .is .regulated .by .state .BON
Proper .RX .- .CORRECT .ANSWER-Providers .name .and .address, .Telephone
DEA
Pt .name/DOB/Addres
Name .of .Drug, .strength, .SIG(directions) .with .indication/Route .and .frequency,
.Quantity .and .signature.
Drug .Schedules: .Most .addictive .to .least .- .CORRECT .ANSWER-1: .Heroin,LSD, .MJ
2: .hydrocodone, .cocaine, .Methamphetamine, .methadone, .oxycodone,
.meperidine, .fentanyl, .adderall, .ritalin
3: .codeine, .ketamine, .testosterone
4: .xanax, .valium, .soma, .ambient, .tramadol
5: .antidiarrheal, .antitussives, .lomotil, .lyrica
Pharmicodyamics .- .CORRECT .ANSWER-The .effects .of .drug .on .the .body.
.Receptors .are .large .molecules .usually .proteins, .that .interact .and .mediate .the
.action .of .drugs
agonist .- .CORRECT .ANSWER-produce .receptor .stimulation .and .a
.conformational .change .every .time .they .bind. .Do .not .need .all .available .receptors
.to .produce .a .maximum .response
Partial .agonist .- .CORRECT .ANSWER-drugs .that .have .properties .in .b/w .those .of
.full .agonist .and .antagonist. .They .bind .to .receptors .but .when .they .occupy .the
.receptor .sites, .they .stimulate .only .some .of .the .receptors.
antagonist .- .CORRECT .ANSWER-drugs .with .affinity .for .a .receptor .but .with .no
.intrinsic .activity. . Affinity .allows .the .antagonist .to .bind .to .receptors, .but .lack .of
.intrinsic .activity .prevents .the .bound .antagonist .from .causing .receptor
.activation. .The .block .action .of .drugs .(ex. .Narcan)
Bioavailabity .- .CORRECT .ANSWER-% .of .administered .dosage .of .the .drug .that
.survives .the .first .pass .through .the .liver .and .reaches .the .blood .stream
,half .life .- .CORRECT .ANSWER-Time .required .for .the .amount .of .a .drug .in .the
.body .to .decline .by .50%, .drugs .with .shorter .half .lives .must .be .administer
.frequently. .4.5-5.5 .times .the .half .life .to .get .steady .state .and .to .be .limited .from
.the .body
what .the .body .does .to .the .drug .- .CORRECT .ANSWER-absorption, .distribution,
.metabolism, .excretion
Distribution .- .CORRECT .ANSWER-movement .of .absorbed .drug .in .bodily .fluids
.throughout .the .body .to .target .tissue. .Properties .affecting: .lipid/water .solubility,
.PH .affects .ionization .of .drug, .protein .binding, .size .of .molecule .(smaller
.molecules .are .more .able .to .diffuse)
Tissue: .fat, .bone, .blood/brain .barrier .(only .lipid .soluble .will .pass), .placental
.barrier .(many .drugs .can .pass)
Protein .binding .- .CORRECT .ANSWER-unbound .drug .is .free .which .is .active,
.crosses .membrane. .Low .plasma .proteins .result .in .more .free .drug. .Competition:
.when .2 . highly .bound .drugs .are .given .it .increases .the .level .of .both .drugs
Metabolism .- .CORRECT .ANSWER-take .place .in .the .liver .mostly. .Chemical
.change .of .a .drug .structure .to: .
Enhance .excretion, .inactivate .the .drug, .increase .therapeutic .action, .active .a
.prodrug .(inactive .until .metabolized .in .the .body .into .the .active .compound, .ex:
.levodopa), .increase .or .decrease .toxicity
CYP450 .- .CORRECT .ANSWER-enzymes .constitutes .the .most .important .of .the
.phase .I .metabolizing .enzymes .(account .for .about .75% .of .drug .metabolism .in .the
.liver)
Phase .2: .conjugation .reaction .occur .leading .to .large .increases .in .hydrophilicity
.of .the .substrates .rendering .them .more .readily .excretable
Substrate .- .CORRECT .ANSWER-an .agent .that .is .metabolized .by .an .enzyme .into
.a .metabolite .and .product .and .eventually .excreted
Inhibitors .- .CORRECT .ANSWER-compete .with .other .drugs .for .a .particular
.enzyme .affecting .the .metabolism .(decreased) .of .the .substrate .and .decreases
.the .excretion .of .the .substrate .and .increasing .the .circulating .drug
inducer .- .CORRECT .ANSWER-competes .with .other .drugs .for .a .particular .enzyme
.affecting .metabolism .of .the .substrate .(increases) .decreasing .the .efficacy .of .the
.drug
excretion .- .CORRECT .ANSWER-renal: .passive .glomerular .filtration, .active
.tubular .secretion, .tubular .reabsorption, .gi .tract, .lung, .sweat .and .salivary,
.mammary
genomics .- .CORRECT .ANSWER-study .of .the .complete .set .of .genetic .information
.present .in .a .cell, .an .organism, .or .species
, pharmacogenetics .- .CORRECT .ANSWER-the .study .of .the .influence .of .hereditary
.factors .on .the .response .of .individual .organisms .to .drugs, .and .the .study .of
.variations .of .DNA .and .RNA .characteristics .as .related .to .drug .response
Pharmacogenetics .tests .- .CORRECT .ANSWER-Mentioned .on .drug .labels .can .be
.classified .as ."test .required," ."test .recommended," .and ."information .only."
.Currently, .four .drugs .are . required .to .have .pharmacogenetics .testing .performed
.before .they .are .prescribed: .cetuximab, .trastuzumab, .maraviroc .and .dasatinib
wafarin, .carbamazepine, .valproic .acid .and .abacavir .are .recommended .to .tests
.prior .to .initial .dosing
Carbamazepine .and .Asisans .- .CORRECT .ANSWER-Initiating .carbamazepine
.therapy .in .these .patients .(allele .HLA-B*1502) .are .at .high .risk .for .developing
.Steven .Johnson .syndrome .or .toxic .epidermal .necrolysis .(TEN)
The .ability .of .the .anesthetic .to .penetrate .the .axon .membrane .is .determined .by .3
.properties. .What .are .they? .- .CORRECT .ANSWER-Molecular .size, .Lipid .solubility,
.degree .of .ionization .at .tissue .pH
Why .is .epinephrine .given .with .local .anesthetics? .- .CORRECT .ANSWER-
Decreases .local .blood .flow .(decreased .risk .of .bleeding)
Delays .systemic .absorption .of .the .anesthetic
prolongs .anesthesia
reduces .the .risk .of .toxicity
What .is .the .most .widely .used .local .anesthetic? .- .CORRECT .ANSWER-Lidocaine
What .is .a .possible .fatal .reaction .to .benzocaine .- .CORRECT .ANSWER-
Methemoglobinemia
What .is .included .in .application .guidelines .for .topical .anesthetics .- .CORRECT
.ANSWER-avoid .wrapping .the .site .and .heating .the .site, .avoid .application .to .open
.skin
Which .medication .will .not .cause .rebound .headaches .from .overuse? .- .CORRECT
.ANSWER-propranolol .(preventative)
What .is .the .best .option .for .menstural .migraine? .- .CORRECT .ANSWER-low .dose
.estrogen .about .3 .days .prior .to .menses
What .food .can .trigger .migraines? .- .CORRECT .ANSWER-Hot .dog .d/t .nitrates
What .medication .is .a .Seratonin .1B1D .receptor .agonist? .- .CORRECT .ANSWER-
Sumatriptan
Butterbur .can .help .as .prevention .for .migraine .therapy. .What .side .effect .can
.occur? .- .CORRECT .ANSWER-Liver .damage
A+ Graded (2025)
Prescribing .basics .- .CORRECT .ANSWER-Prescribing .is .regulated .by .state .BON
Proper .RX .- .CORRECT .ANSWER-Providers .name .and .address, .Telephone
DEA
Pt .name/DOB/Addres
Name .of .Drug, .strength, .SIG(directions) .with .indication/Route .and .frequency,
.Quantity .and .signature.
Drug .Schedules: .Most .addictive .to .least .- .CORRECT .ANSWER-1: .Heroin,LSD, .MJ
2: .hydrocodone, .cocaine, .Methamphetamine, .methadone, .oxycodone,
.meperidine, .fentanyl, .adderall, .ritalin
3: .codeine, .ketamine, .testosterone
4: .xanax, .valium, .soma, .ambient, .tramadol
5: .antidiarrheal, .antitussives, .lomotil, .lyrica
Pharmicodyamics .- .CORRECT .ANSWER-The .effects .of .drug .on .the .body.
.Receptors .are .large .molecules .usually .proteins, .that .interact .and .mediate .the
.action .of .drugs
agonist .- .CORRECT .ANSWER-produce .receptor .stimulation .and .a
.conformational .change .every .time .they .bind. .Do .not .need .all .available .receptors
.to .produce .a .maximum .response
Partial .agonist .- .CORRECT .ANSWER-drugs .that .have .properties .in .b/w .those .of
.full .agonist .and .antagonist. .They .bind .to .receptors .but .when .they .occupy .the
.receptor .sites, .they .stimulate .only .some .of .the .receptors.
antagonist .- .CORRECT .ANSWER-drugs .with .affinity .for .a .receptor .but .with .no
.intrinsic .activity. . Affinity .allows .the .antagonist .to .bind .to .receptors, .but .lack .of
.intrinsic .activity .prevents .the .bound .antagonist .from .causing .receptor
.activation. .The .block .action .of .drugs .(ex. .Narcan)
Bioavailabity .- .CORRECT .ANSWER-% .of .administered .dosage .of .the .drug .that
.survives .the .first .pass .through .the .liver .and .reaches .the .blood .stream
,half .life .- .CORRECT .ANSWER-Time .required .for .the .amount .of .a .drug .in .the
.body .to .decline .by .50%, .drugs .with .shorter .half .lives .must .be .administer
.frequently. .4.5-5.5 .times .the .half .life .to .get .steady .state .and .to .be .limited .from
.the .body
what .the .body .does .to .the .drug .- .CORRECT .ANSWER-absorption, .distribution,
.metabolism, .excretion
Distribution .- .CORRECT .ANSWER-movement .of .absorbed .drug .in .bodily .fluids
.throughout .the .body .to .target .tissue. .Properties .affecting: .lipid/water .solubility,
.PH .affects .ionization .of .drug, .protein .binding, .size .of .molecule .(smaller
.molecules .are .more .able .to .diffuse)
Tissue: .fat, .bone, .blood/brain .barrier .(only .lipid .soluble .will .pass), .placental
.barrier .(many .drugs .can .pass)
Protein .binding .- .CORRECT .ANSWER-unbound .drug .is .free .which .is .active,
.crosses .membrane. .Low .plasma .proteins .result .in .more .free .drug. .Competition:
.when .2 . highly .bound .drugs .are .given .it .increases .the .level .of .both .drugs
Metabolism .- .CORRECT .ANSWER-take .place .in .the .liver .mostly. .Chemical
.change .of .a .drug .structure .to: .
Enhance .excretion, .inactivate .the .drug, .increase .therapeutic .action, .active .a
.prodrug .(inactive .until .metabolized .in .the .body .into .the .active .compound, .ex:
.levodopa), .increase .or .decrease .toxicity
CYP450 .- .CORRECT .ANSWER-enzymes .constitutes .the .most .important .of .the
.phase .I .metabolizing .enzymes .(account .for .about .75% .of .drug .metabolism .in .the
.liver)
Phase .2: .conjugation .reaction .occur .leading .to .large .increases .in .hydrophilicity
.of .the .substrates .rendering .them .more .readily .excretable
Substrate .- .CORRECT .ANSWER-an .agent .that .is .metabolized .by .an .enzyme .into
.a .metabolite .and .product .and .eventually .excreted
Inhibitors .- .CORRECT .ANSWER-compete .with .other .drugs .for .a .particular
.enzyme .affecting .the .metabolism .(decreased) .of .the .substrate .and .decreases
.the .excretion .of .the .substrate .and .increasing .the .circulating .drug
inducer .- .CORRECT .ANSWER-competes .with .other .drugs .for .a .particular .enzyme
.affecting .metabolism .of .the .substrate .(increases) .decreasing .the .efficacy .of .the
.drug
excretion .- .CORRECT .ANSWER-renal: .passive .glomerular .filtration, .active
.tubular .secretion, .tubular .reabsorption, .gi .tract, .lung, .sweat .and .salivary,
.mammary
genomics .- .CORRECT .ANSWER-study .of .the .complete .set .of .genetic .information
.present .in .a .cell, .an .organism, .or .species
, pharmacogenetics .- .CORRECT .ANSWER-the .study .of .the .influence .of .hereditary
.factors .on .the .response .of .individual .organisms .to .drugs, .and .the .study .of
.variations .of .DNA .and .RNA .characteristics .as .related .to .drug .response
Pharmacogenetics .tests .- .CORRECT .ANSWER-Mentioned .on .drug .labels .can .be
.classified .as ."test .required," ."test .recommended," .and ."information .only."
.Currently, .four .drugs .are . required .to .have .pharmacogenetics .testing .performed
.before .they .are .prescribed: .cetuximab, .trastuzumab, .maraviroc .and .dasatinib
wafarin, .carbamazepine, .valproic .acid .and .abacavir .are .recommended .to .tests
.prior .to .initial .dosing
Carbamazepine .and .Asisans .- .CORRECT .ANSWER-Initiating .carbamazepine
.therapy .in .these .patients .(allele .HLA-B*1502) .are .at .high .risk .for .developing
.Steven .Johnson .syndrome .or .toxic .epidermal .necrolysis .(TEN)
The .ability .of .the .anesthetic .to .penetrate .the .axon .membrane .is .determined .by .3
.properties. .What .are .they? .- .CORRECT .ANSWER-Molecular .size, .Lipid .solubility,
.degree .of .ionization .at .tissue .pH
Why .is .epinephrine .given .with .local .anesthetics? .- .CORRECT .ANSWER-
Decreases .local .blood .flow .(decreased .risk .of .bleeding)
Delays .systemic .absorption .of .the .anesthetic
prolongs .anesthesia
reduces .the .risk .of .toxicity
What .is .the .most .widely .used .local .anesthetic? .- .CORRECT .ANSWER-Lidocaine
What .is .a .possible .fatal .reaction .to .benzocaine .- .CORRECT .ANSWER-
Methemoglobinemia
What .is .included .in .application .guidelines .for .topical .anesthetics .- .CORRECT
.ANSWER-avoid .wrapping .the .site .and .heating .the .site, .avoid .application .to .open
.skin
Which .medication .will .not .cause .rebound .headaches .from .overuse? .- .CORRECT
.ANSWER-propranolol .(preventative)
What .is .the .best .option .for .menstural .migraine? .- .CORRECT .ANSWER-low .dose
.estrogen .about .3 .days .prior .to .menses
What .food .can .trigger .migraines? .- .CORRECT .ANSWER-Hot .dog .d/t .nitrates
What .medication .is .a .Seratonin .1B1D .receptor .agonist? .- .CORRECT .ANSWER-
Sumatriptan
Butterbur .can .help .as .prevention .for .migraine .therapy. .What .side .effect .can
.occur? .- .CORRECT .ANSWER-Liver .damage
